Year: 2014
Type: article
Abstract: We have previously shown that inhibition of the MEK pathway with selumetinib greatly reduced T cell proliferation induced by allo-DC stimulation with minimal loss in virus-specific cytokine production in EBV and CMV-stimulated T cells in vitro, and that selumetinib significantly reduced GVHD and increased survival in a GVHD mouse model. Thus, MEK inhibitors represent a novel class of immunosuppressive agents that potentially target GVHD initiation while sparing beneficial immunity in the allo-SCT setting.
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2321583712